ER-positive breast cancer has a sustained risk of disease recurrence and death. High risk patients may receive extended endocrine therapy. Breast cancer-specific mortality of ER+ patients treated from 1990 to 2005 through SEER database were analyzed. A risk classification model was designed to identify patients with high late recurrence risk for extended endocrine therapy.